Type 2 Diabetes Clinical Trials in Baltimore, Maryland

6 studies are recruiting for type 2 diabetes in Baltimore, Maryland right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication

   The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of semaglutide in people with overweight or obesity, with or without type 2 diabetes (T2D). All participants will get semaglutide and zenagamtide.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   PAREXEL Intl - EPCU-Baltimore, Baltimore, Maryland

   Locations

   2 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07855133 on ClinicalTrials.gov

2. A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication

   The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of tirzepatide in people with overweight or obesity, with or without type 2 diabetes (T2D). All participants will get tirzepatide and zenagamtide.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   PAREXEL Intl - EPCU-Baltimore, Baltimore, Maryland

   Locations

   2 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07868354 on ClinicalTrials.gov

3. Multimodal Glucose Prediction in Type 2 Diabetes

   The primary objective of this research, funded by Samsung Strategic Alliance for Research and Technology, is to develop multi-modal foundation models that integrate Continuous Glucose Monitoring (CGM) data with patient behavior data (food intake, medication, and physical activity) to improve real-t…

   Stage

   Not phased

   Ages

   18 to 75

   Site

   Johns Hopkins Medicine, Baltimore, Maryland

   Run by

   Johns Hopkins University

   See if you can join NCT07633171 on ClinicalTrials.gov

4. ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2

   The purpose of this study is to determine if use of a nonmydriatic fundus camera using autonomous artificial intelligence software at the point of care increases the proportion of underserved youth with diabetes screened for diabetic retinopathy, and to determine the diagnostic accuracy of the auto…

   Stage

   Not phased

   Ages

   8 to 21

   Site

   Johns Hopkins Pediatric Diabetes Center, Baltimore, Maryland

   Run by

   Johns Hopkins University

   See if you can join NCT05463289 on ClinicalTrials.gov

5. AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

   This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already taking 1 to 3 diabetes medications. There are 2 study treatments in thi…

   Stage

   Phase 3

   Ages

   45 and older

   Site

   Ascension Saint Agnes Heart Ca, Baltimore, Maryland

   Locations

   330 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07797335 on ClinicalTrials.gov

6. A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

   The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.

   Stage

   Phase 3

   Ages

   10 to 17

   Site

   Johns Hopkins University School of Medicine, Baltimore, Maryland

   Locations

   51 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06739122 on ClinicalTrials.gov